BioWorld

Dec. 20, 2007

View Archived Issues

Idera Signs $421M Deal For TLR9 Cancer Agonists

The deal-making furor surrounding Toll-like receptors (TLRs) is continuing, with Merck KGaA agreeing to pay up to $421 million for worldwide rights in cancer indications to Idera Pharmaceuticals Inc.'s for TLR9 agonists. (BioWorld Today) Read More

Galapagos Inks $395M Deal With Lilly For Osteo Drugs

Read More

Santaris Gets $700M From GSK In Antiviral LNA-Based Drug Pact

Read More

London Leukemia Case Linked To Gene Therapy

Read More

Alkermes Gets $166M Boost From GSK's Reliant Buyout

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More

Appointments And Advancements

Read More